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Summary A trial of FAA and rIL-2 has been performed both to study the clinical efficacy of this
combination and to determine whether they cause haemorrhagic necrosis by acting upon tumour vasculature.
FAA and rIL-2 were given to 23 patients with progressing metastatic melanoma. FAA 4.8 gm m-2 was given
as a I h infusion without urine alkalinisation on days 1, 8 and 15. rIL-2 (6-18 x 106 iu/m2/day) was given as a
continuous infusion days 8-12 and 15-19 (nine patients) or days 8-12 only (14 patients). Treatment was
repeated after 2 weeks unless there was disease progression. Of the 21 assessable patients there have been one
complete (skin and liver) and two partial responses (skin and liver, skin and nodes) lasting 20 + 17 + and 15
months, overall response rate 14%. Unexpectedly severe hypotension after the third FAA, when given 2-4
days after RIL-2, was the major toxicity (8/15 grade 3 or 4). No alteration in coagulation parameters were
seen during therapy of the first ten patients. No increase in tumour necrosis was seen in any of the 15 biopsies
taken from ten patients after therapy. This suggests that FAA does not have similar vascular effects in human
as it does in murine tumours.
Flavone acetic acid (FAA) is a synthetic flavonoid which is
highly active against a wide variety of murine solid tumours
including melanoma (Corbett et al., 1986). It is not directly
cytotoxic, but in most studies its activity is dependent on the
host having an intact immune system and the tumour having
an established vasculature (Bibby et al. 1987; Bibby et al.,
1991). Despite the impressive anti-tumour activity noted in
animal tumour models, extensive Phase II testing of FAA as
a single agent has failed to demonstrate any activity in man
(Kerr et al., 1989).
Haemorrhagic necrosis is seen to occur rapidly in animal
tumours after FAA and is though to be one component of its
method of action (Smith et al., 1987). As it is unknown
whether this vascular effect occurs in humans we set up a
further trial of FAA in patients with superficial tumours that
could be biopsied. Other changes seen in animals after FAA
such as a fall in platelets, a rise in nitrate levels and changes
in cytokines were also studied and are reported elsewhere
(Thomsen et al., 1992; Haworth et al., 1993). We also
assessed whether these changes were associated with varia-
tions in FAA pharamacokinetics (Stratford et al., 1993).
To improve the chance of seeing anti-tumour activity we
gave FAA without alkalinising the urine. Bicarbonate has
been given in most human studies to prevent crystallisation
of FAA in the acidic tubules but it is now known that this
also inhibits its activity against animal tumours (Denekamp
& Hill, 1991). To enhance anti-tumour activity further, after
an initial infusion of FAA we combined it with interleukin-2
(IL-2) which has known single agent activity against
Table I Patient characteristics
No. of patients 23
Age mean 55
range (21 -74)
ECOG performance status
0/1 15
2 5
3 3
Previous chemotherapy 6
Dominant sites of disease
Soft tissue/nodes 9
Liver 9
Lung 4
Bone 1
melanoma and renal carcinoma (Rosenberg, 1992). The com-
bination of FAA and IL-2 has been shown to be synergistic
both in the induction of lymphocyte activated killer cells and
in the treatment of murine renal carcinoma (Wiltrout et al.,
1988). The combination has been investigated in melanoma
patients by Thatcher and colleagues (1990) without an imp-
roved response rate compared with that expected from treat-
ment with IL-2 alone. In contrast to his study FAA was
given weekly, before and after IL-2,,rather than just once
before IL-2 and over 1 rather than 6 h as vascular damage is
more likely after a rapid infusion (Denekamp & Hill, 1991).
Materials and methods
Patientspopulation
Twenty three patients with metastatic melanoma were
entered into this study. All patients had clinically evaluable
disease and no patient had received cytotoxic treatment
within the 4 weeks preceding study entry. Patient characteris-
tics are summarised in Table I. Of note, 8/23 (35%) had a
poor (ECOG 2/3) performance status on entry into the study.
Fourteen patients (61%) had predominantly visceral metas-
tatic disease including nine patients (39%) with liver metas-
tases.
Treatment
In order to facilitate treatment, all patients had a Hickman
catheter inserted prior to treatment. In the initial study pro-
tocol, FAA 4.8 gm m-2 (kindly supplied by Lipha, Lyon)
was given as a 1 hour infusion in 500 mls of0.9% saline with
light protection days 1, 8 and 15. A continuous intravenous
infusion of rIL-2 18 x 106 iu/m2/day reconstituted in 5%
dextrose and 2% albumin was given between days 8 and 12
and again between days 15 and 19 to the first nine patients.
The days 15 to 19 course of IL-2 was omitted for subsequent
patients in light oftoxicity. A second course of treatment was
given after a 14 day interval unless there was evidence of
disease progression. A maximum of two courses of treatment
were given.
Sample collection
Blood samples were taken pretreatment and at 1,2,4,6 and
24 h after FAA and daily during IL-2 infusions. Coagulation
was assessed by measuring platelets, prothrombin time, par-
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tial thromboplastin time, fibrinogen levels and fibrin degrada-
tion products. Plasma for estimation of nitrate levels and
serum for cytokine levels were stored at - 200 until analysis.
The vascular effect of treatment was assessed indirectly by
estimating the extent of tumour necrosis after therapy.
Sequential biopsies of cutaneous or subcutaneous tumour
nodules were obtained when possible using 2% lignocaine for
local anaesthesia. Biopsies were fixed in formalin and subse-
quently haematoxylin and eosin stained sections were
examined. The degree of tumour necrosis was assessed by
M.B. and was expressed as a percentage of the total tumour
visible.
Response and toxicity evaluation
Response and toxicity were assessed according to standard
WHO criteria. A complete response (CR) was recorded if
there was disappearance of all known disease for a period of
at least 4 weeks and a partial response was recorded if there
was a reduction of at least 50% in the sum of the products of
the perpendicular diameters of measurable lesions lasting at
least four weeks, with no new lesions noted. Hypotension
was graded on a four point scale. Grade 1 hypotension was a
change of >20 mmHg in systolic pressure; grade 2 hypoten-
sion was a change of >30 mmHg, not requiring fluid
therapy; grade 3 hypotension was a change in systolic pres-
sure requiring fluid therapy and grade 4 hypotension was a
change in systolic blood pressure requiring pressor treatment.
Results
Response
One patient was withdrawn from the study after day I FAA
because brain metastases, previously undetected, were
observed on CT scan and it was decided that he should
receive cranial irradiation. One patient withdrew himself
from the study before completing the first cycle of treatment.
Of the remaining 21 patients assessable for response, one
complete response and two partial responses were noted,
giving an overall response rate of 14%. The complete re-
sponse was in a patient with subcutaneous metastases and
liver metastases and has been maintained for 20 + months.
One other patient had a complete response in liver metastases
(Figure 1) and resolution of >90% of subcutaneous metas-
tases, maintained for 17 + months. The third responding
patient had a partial response in cutaneous and nodal disease
lasting 15 months. All responses were showing clinical
evidence of response to treatment before starting the second
course of treatment and the response rate for patients who
had no evidence of progression by the start of the second
cycle was 3/10 (30%).
Toxicity
A total of 83 courses of FAA (alone or in combination with
IL-2) and 39 courses of IL-2 were given. No serious side
effects were observed after the day 1 FAA although the
majority of patients noted some transient visual disturbance,
with flashing lights, during the FAA infusion and 10/23
patients had mild (WHO grade 1/2) gastrointestinal toxicity,
which also was shortlived. All patients had at least grade 2
pyrexia during the IL-2 unfusion accompanied, in almost all
cases, by lethargy. and myalgia.
However, the most serious side effect observed was a pro-
found drop is systolic blood pressure and the data for
hypotension during the first course of treatment are sum-
marised in Table II. No significant drop in systolic blood
pressure was noted in any patient after day 1 FAA alone.
Significant (grade 3 or 4) hypotension was noted during the
day 8-12 infusion of 11-2 in 5/22 (23%) of patients but this
resolved quickly with colloid infusion after stopping IL-2.
The most profound hypotension was noted 5-24 h after
starting the day 15 treatment, which also consisted of FAA
followed by an infusion of IL-2. Severe hypotension, requir-
b
Figure 1 a, Pretreatment scan (October 1990). b, Liver metastasis in partial remission (March 1991). Repeat CT scan and
ultrasound of liver in October 1991 showed no evidence of liver metastasis.1344 S.M. O'REILLY et al.
Table II The relationship between treatment and hypotension
Treatment No. Grade 3/4 hypotension (%)
FAA day 1 23 0 (0%)
FAA day 8 + IL-2 infusion 22 5 (23%)
FAA day 15 + 11-2 infusion 8 4 (50%)
FAA day 15 alone 7 4 (57%)
ing pressor support for >24 h, was observed in three of the
first eight patients treated. This hypotension was attributed
to the reintroduction of IL-2 two days after stopping the
initial infusion and, accordingly, the treatment protocol was
modified so that the next two patients received no treatment
after day 12. As neither patient developed hypotension and
as FAA alone given on day 1 was not associated with a
significant fall in blood pressure in any patient, day 15 FAA
without the IL-2 infusion was reintroduced for the next 7
patients. However, severe hypotension was again noted in 4/7
patients (57%) despite the omission of IL-2. All patients
receiving FAA alone 2-4 days after IL-2, experienced fevers
and rigors which were similar to those associated with IL-2.
Coagulation studies
Platelet count, prothrombin time, partial thromboplastin
time, fibrinogen levels and fibrin degradation products were
measured before each FAA treatment, at 1, 2, 4, 6 and 24 h
after FAA, and daily during IL-2 infusions for the first ten
patients. Apart from a transient thrombocytopaenia in one
patient at the end of a five day infusion of IL-2, which
resolved quickly spontaneously, no alterations in any
coagulation parameters were observed. Coagulation studies
were therefore omitted for the subsequent 13 patients.
Serial tumour biopsies
Biopsies of subcutaneous or cutaneous metastatic lesions
were obtained at some point during the first course of treat-
ment from a total of ten patients, including the three respon-
ding patients, although serial biopsies both before and during
therapy were obtained in only five patients (Table III). Of
note, necrotic tumour occupying >30% of the specimen was
noted in two of the five pretreatment biopsies. Biopsies after
day 1 FAA (ie FAA given as a single agent, without IL-2)
were obtained at time points ranging from 2 to 52 h after
treatment, and one patient had 3 biopsies performed during
the 36 h period. Only one specimen, from a patient who had
not had a pre-treatment biopsy, had >30% necrotic tumour
and, in one patient, the proportion of necrotic tumour was
30-50% in the pretreatment specimen, but <5% in the
biopsy obtained 20 h after IL-2. There was no relationship
between the degree of tumour necrosis observed in the biopsy
specimens and the eventual response to treatment.
Discussion
Extensive haemorrhagic necrosis is seen in most murine
tumours within a few hours of an adequate dose of FAA.
This is the first study to investigate whether similar necrosis
is seen in human tumours. If it was, any lack of associated
tumour response could be due either to the degree of necrosis
being inadequate, or the requirement of additional possibly
immune factors. There was no evidence of an increase in
haemorrhagic necrosis in any of the 20 biopsies taken from 2
to 178 h after FAA. The lack of increased necrosis seen in
the biopsies from the three patients whose tumours later
responded, suggest that the response was due to a delayed
effect, possibly entirely due to the IL-2. However, these
results must be interpreted with caution as patchy necrosis
can be missed on random samples.
We found no evidence that FAA either given alone or in
combination with IL-2 disrupted clotting mechanisms. This
information plus the lack of any increase in tumour necrosis
in any of our biopsies, indicates that in contrast to its actions
in mice, FAA lacks activity against human tumour vas-
culature. We did not investigate the fibrinolytic pathway
which has been shown previously to be deranged by IL-2.
Tumour necrosis factor (TNF) is thought to mediate the
haemorrhagic necrosis and anti tumour effect of FAA as this
effect is blocked by antibodies to TNF (Mahadevan et al.,
1990; Pratesi et al., 1990). We have shown a modest elevation
of TNF levels after the combination of FAA and IL-2 but
not after IL-2 alone (Haworth et al., 1993). The lack of
haemorrhagic necrosis seen in five biopsies taken after com-
bined FAA and IL-2 therapy, could be due to lack of tumour
selectivity of any cytokine release.
The major toxicity noted in this study was profound
hypotension. This occurred predominantly after the day 15
FAA, irrespective of whether this FAA was followed by an
infusion of IL-2 or not. As FAA given alone before the IL-2
infusion did not cause significant hypotension in any
patients, the drop in blood pressure observed in the majority
of patients after the day 15 FAA must be attributed to a
synergistic action between FAA and the IL-2 infusion which
had stopped 2 days previously. This affect coincides with the
rebound lymphocytosis seen after stopping IL-2. The symp-
toms are suggestive of a massive cytokine release through the
action of FAA on these IL-2 primed cells. Some evidence to
support this hypothesis has come from the cytokine estima-
tions performed as part of this protocol (Haworth et al.,
1993), where induction of IL-6 and GMCSF appeared to be
induced by the day 15 FAA. Nitrate levels were also highest
at this time (Thomsen et al., 1992). There was no relationship
between the degree of hypotension and the eventual response
to treatment.
Because of the impressive activity of FAA against murine
tumours, analogues have been produced. It will be essential
to look for the occurrence of specific tumour haemorrhagic
necrosis and non specific cytokine release when studying
these agents in man. As it is difficult to obtain human
Table III Necrosis in tumour nodules after FAA and IL-2
FAA FAA IL-2 FAA
Pre I I 1111 I
Responders
1 <5% (+ 2)<5% (+ 24) <5%
2 30-50% (+ 20)<5%
3 < 10% (+ 52)<10%
Nonresponders
4 >50% (+ 27)<5% (+ 29) <5%
5 <5% (+ 24)<5%
6 (+ 24)
7 (+ 24)30-50%
8 (+5,22
and 36)<10% (+ 178) <5%
9 (+ 24)<5%
10 (+ 24)<5%
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tumour biopsies after therapy, indirect indications of
haemorrhagic necrosis such as cytokine, or nitric oxide
induction (Thomsen et al., 1992) should be measured.
Objective response to treatment was noted in 3/21 (14%)
assessable patients, six of whom were of poor performance
status and would have been excluded from many IL-2
studies. This response rate is similar to that reported by
Thatcher and colleagues (1990) and not higher than that
which would be expected using IL-2 alone. However, the
responses were obtained using a much lower dose of IL-2
than that used in the Thatcher's study (90 x 106 iu/m2/course
compared with 330 x 106/m2/course), with attendant implica-
tions for the cost of treatment. The fact that two patients
experienced complete remission of liver metastases which
have been maintained for 17 + and 20 + months after just 7
weeks treatment suggests that further studies are required of
flavonoids and IL-2.
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